INS and fatty liver disease: Previous research showed that supplementation with Lovaza, an n-3 drug, enhances lipid metabolism, reduces hepatic steatosis, downregulates lipogenic gene expression, stimulates beta-oxidation, and improves insulin sensitivity in murine models [35].